In vitro studies showed that the combination of JAK2 and BET inhibition resulted in enhanced cell apoptosis and the growth arrest of blastic cells from post-MPN AML [191], while in preclinical animal models of myelofibrosis it was able to reduce fibrosis and prolong survival [192]. This evidence concerns the gene JAK2 and acute myeloid leukemia.